Minerva Neurosciences Inc (4MN)

0.7810
-0.0095(-1.20%)
  • Volume:
    0
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    0.7810 - 0.7810
  • Type:Equity
  • Market:Germany
  • ISIN:US6033801068
  • WKN:A1171S

4MN Overview

Prev. Close
0.7905
Day's Range
0.781-0.781
Revenue
-
Open
0.781
52 wk Range
0.723-3
EPS
-
Volume
0
Market Cap
35.52M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,383
P/E Ratio
-
Beta
-
1-Year Change
-66.79%
Shares Outstanding
42,721,566
Next Earnings Date
-
What is your sentiment on Minerva Neurosciences Inc?
or
Vote to see community's results!

Minerva Neurosciences Inc Company Profile

Employees
11

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.